PCRX - Pacira BioSciences, Inc.

24.88
0.240   0.965%

Share volume: 357,185
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$24.64
0.24
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 26%
Dept financing 14%
Liquidity 70%
Performance 43%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.08%
1 Month
9.85%
3 Months
20.37%
6 Months
14.87%
1 Year
-1.27%
2 Year
-7.20%
Key data
Stock price
$24.88
P/E Ratio 
158.29
DAY RANGE
$24.42 - $25.12
EPS 
$0.16
52 WEEK RANGE
$18.80 - $27.64
52 WEEK CHANGE
-$4.31
MARKET CAP 
1.113 B
YIELD 
N/A
SHARES OUTSTANDING 
40.490 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$448,062
AVERAGE 30 VOLUME 
$509,457
Company detail
CEO: David M. Stack
Region: US
Website: pacira.com
Employees: 720
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.

Recent news